Results 31 to 40 of about 1,172,272 (355)

Multiparametric magnetic resonance imaging of the prostate-a basic tutorial. [PDF]

open access: yes, 2017
Prostate cancer is the second most common cause of cancer related death in the United States and the most commonly diagnosed malignancy in men. In general, prostate cancer is slow growing, though there is a broad spectrum of disease that may be indolent,
Cabarrus, Miguel C   +1 more
core   +1 more source

SETD2, GIGYF2, FGFR3, BCR, KMT2C, and TSC2 as candidate genes for differentiating multilocular cystic renal neoplasm of low malignant potential from clear cell renal cell carcinoma with cystic change [PDF]

open access: yesInvestigative and Clinical Urology, 2019
Purpose: Multilocular cystic renal neoplasm of low malignant potential (MCRNLMP) and clear cell renal cell carcinoma with cystic change (MCRCC) have different prognoses despite similar histologic characteristics.
Sung Han Kim   +2 more
doaj   +1 more source

Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study [PDF]

open access: yesInvestigative and Clinical Urology, 2020
Purpose: This study aimed to compare progression-free survival (PFS), overall survival (OS), and cancer-specific survival (CSS) in Heng intermediate-risk patients with metastatic renal cell carcinoma (mRCC) treated with first-line immunotherapy (IT) or ...
Sung Han Kim   +5 more
doaj   +1 more source

Inflammation in benign prostate tissue and prostate cancer in the finasteride arm of the Prostate Cancer Prevention Trial [PDF]

open access: yes, 2016
BACKGROUND: A previous analysis of the placebo arm of the Prostate Cancer Prevention Trial (PCPT) reported 82% overall prevalence of intraprostatic inflammation and identified a link between inflammation and higher-grade prostate cancer and serum PSA ...
Barber, John R   +15 more
core   +2 more sources

Evaluating whether Prostate Cancer UK’s risk checker is a help or hindrance to prostate-specific antigen testing policy: a mixed-methods study

open access: yesBJGP Open
Background: The UK has an informed choice testing policy for prostate cancer. The prostate-specific antigen (PSA) blood test is available for free to any man aged ≥50 years who requests it and has been informed of the harms and benefits.
Natalia Norori   +8 more
doaj   +1 more source

Publisher Correction: Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy

open access: yesNature Communications, 2019
The original version of this Article contained errors in Fig. 7. In panels e and f, the graph titles incorrectly read ‘LNCaP-AdtNs’ and ‘LAPC4-AdtNs’, respectively. These errors have now been corrected in both the PDF and HTML versions of the Article.
Hao Geng   +16 more
doaj   +1 more source

Increasing the attractiveness of surgical disciplines for students: Implications of a robot-assisted hands-on training course for medical education

open access: yesFrontiers in Surgery, 2022
BackgroundStructured implementation of robot-assisted surgery in the field of medical education is lacking. We assessed students' interest in robot-assisted surgery and tested if the implementation of a hands-on robotic course into the curriculum could ...
Jonas Ekrutt   +8 more
doaj   +1 more source

Projecting prevalence by stage of care for prostate cancer and estimating future health service needs: protocol for a modelling study [PDF]

open access: yes, 2016
Introduction Current strategies for the management of prostate cancer are inadequate in Australia. We will, in this study, estimate current service needs and project the future needs for prostate cancer patients in Australia.
Clements, M. S.   +5 more
core   +1 more source

Conducting Clinical Research in Low Research Resource Countries: Lessons Learned From the International Registry of Men With Advanced Prostate Cancer Study in Nigeria

open access: yesJCO Global Oncology
PURPOSEThere is limited cancer clinical research in sub-Saharan African countries despite the significant burden of cancers. The primary objective of this strengths, weaknesses, opportunities, and threats (SWOT) analysis was to understand and document ...
Opeyemi Bolajoko   +13 more
doaj   +1 more source

Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine

open access: yesGenome Medicine, 2023
Background Prostate cancer (PrCa) genomic heterogeneity causes resistance to therapies such as androgen deprivation. Such heterogeneity can be deciphered in the context of evolutionary principles, but current clinical trials do not include evolution as ...
Anssi Nurminen   +24 more
doaj   +1 more source

Home - About - Disclaimer - Privacy